Los Altos, CA, United States of America

Stephen A Tillson

This inventor holds 2 USPTO granted patents. Top assignee: Alza Corporation. Active years: 1977.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 1977

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Stephen A. Tillson

Introduction

Stephen A. Tillson is an accomplished inventor based in Los Altos, California. He has made significant contributions to the field of medical treatments, particularly in addressing women's health issues. With a total of 2 patents to his name, Tillson's work focuses on innovative methods for treating dysmenorrhea and hypermenorrhea.

Latest Patents

Tillson's latest patents include a method for treating dysmenorrhea with a uterine therapeutic system. This method involves administering controlled and continuous low dosage amounts of a progestational hormone to the uterus of a warm-blooded animal suffering from dysmenorrhea, providing symptomatic relief. Additionally, he has developed a method for treating hypermenorrhea using a similar approach, which entails continuously administering controlled low dosage amounts of a progestational hormone to the uterus to alleviate hypermenorrhea.

Career Highlights

Stephen A. Tillson has been associated with Alza Corporation, where he has contributed to various innovative projects. His expertise in medical treatments has positioned him as a valuable asset in the field of women's health.

Collaborations

Some of Tillson's notable coworkers include Bruce B. Pharriss and Ross R. Erickson, who have collaborated with him on various projects within Alza Corporation.

Conclusion

Stephen A. Tillson's innovative approaches to treating dysmenorrhea and hypermenorrhea highlight his commitment to improving women's health through scientific advancements. His contributions continue to influence the medical field positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…